Navigation Links
Cancer treatment, artery repair are goals of $3 million in NIH grants
Date:2/18/2014

The National Institutes of Health has awarded grants totaling $3 million for two nanoparticle research projects in which Penn State bioengineer Jian Yang is co-principal investigator. Drawing upon biology and materials science, the researchers will develop new polymers designed to deliver targeted cancer drugs and repair damaged arteries.

Yang and co-PI Jer-Tsong Hsieh of the University of Texas Southwestern Medical Center received $1.6 million over five years to develop biodegradable nanoparticles to image and treat prostate cancer.

Prostate cancer is the second leading cause of cancer death in American men. If the cancer develops treatment resistance, the tumors grow and spread to other parts of the body. To prevent that, Yang and Hsieh will try to identify a prostate cancer-specific drug called a genotoxin that will attack the cancer cells, and also a fluorescent nanoparticle that targets those cancer cells.

Yang's group plans to add magnetic resonance imaging particles to the fluorescent nanoparticles in order to find the exact location of the tumor. If surgical removal of the cancer is required, fluorescent nanoparticles could attach to cancer cells and help the surgeon identify those small clusters of cancer cells that are usually invisible to the eye.

"We will need to optimize the genotoxin, and make sure we can put it into the nanoparticle," Yang said. "Then we will have to tune the nanoparticle to emit strong fluorescence, and also control the release of the drug into the tumor and not the bloodstream."

Yang and co-PI Kytai Truong Nguyen of the University of Texas Arlington received $1.4 million over four years to develop nanoparticles that promote healing in damaged endothelium, the lining of blood vessels, which can be injured in surgical procedures that unblock clogged arteries.

"Angioplasty and stenting often damage arterial walls, with a significant risk of subsequent complications, such as re-narrowing of the artery or blood clot," Yang said.

Platelets accumulate on the damaged vessel, initiating clot formation. Other cells can deposit on the damaged vessel wall, building up a blockage. The result is multiple traumatic angioplastic and stenting procedures.

The researchers propose to develop a polymer nanoparticle that mimics platelets in the blood that form the clot and create a cover over the damage. Their nanoparticle is decorated with a molecule called GP1b peptide that links to the injured vessel wall and with an anti-CD34 antibody that catches the circulating endothelial progenitor cells that can grow into mature endothelial cells. Over time, the nanoparticles will degrade harmlessly as the new blood vessel lining repairs the damage, avoiding the need for a stent.

A surgeon will still do angioplasty first, according to Yang, but not put in a stent. The nanoparticle solution will be injected instead.

"Once our nanoparticles attach to the vessel wall, the platelets cannot attach," Yang said. "The nanoparticles can outperform the platelets for vessel wall binding due to their smaller sizes. Then the nanoparticles will catch the circulating endothelial progenitor cells to repair the injured vessel wall.

Once their missions are done, the nanoparticles will simply disappear without causing any long-term toxicity. These injectable nanoparticles have worked well in animal models in studies with our collaborators at UT Arlington."


'/>"/>
Contact: A'ndrea Elyse Messer
aem1@psu.edu
814-865-9481
Penn State
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. New Stool Test Might Aid in Early Detection of Colon Cancer
3. Study reveals how cancer drug causes diabetic-like state
4. How a cancer drug leads to diabetes
5. You Survived Cancer: Now Pay Attention to Your Overall Health
6. New drug prevents spread of human prostate cancer cells
7. Eliminating the good cholesterol receptor may fight breast cancer
8. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
9. Experimental Chemo Combo for Colon Cancer Disappoints
10. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
11. Targeted therapeutics for colon cancer to be presented at AACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... financial consultation services to families and business owners in the Dalton region, is ... support for children overcoming sexual assault and physical abuse. , The GreenHouse is ...
(Date:7/21/2017)... ... ... The Ellis Agency, an eastern Georgie provider of insurance management and financial ... event with the goal of bringing in support for epilepsy patients in the greater ... recently launched a charity campaign of her own by donating her birthday to the ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... and financial planning services to communities in the greater Birmingham area, is joining ... resources to underprivileged young people in the region. , The Chris Hammond Youth ...
(Date:7/21/2017)... ... July 21, 2017 , ... Fresh Wave® IAQ today announced the launch of ... colleges and universities at the APPA 2017 Annual Conference and Exhibition in ... smoke odors without the use of harsh chemicals, Fresh Wave IAQ Smoke Away Air ...
(Date:7/21/2017)... Connecticut (PRWEB) , ... July 21, 2017 , ... Hospital ... from HealthCareMandA.com . The number of hospital acquisitions rose to 23 in the ... of 2017, and up 15% from the 20 announced deals in the year-ago second ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... JERUSALEM , July 11, 2017 Oramed ... ), a clinical-stage pharmaceutical company focused on the development ... U.S. Food and Drug Administration (FDA) has agreed to ... successfully completed Phase IIb trial of its oral insulin ... The Phase IIb trial met primary and secondary endpoints ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences Inc. ... to support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing ... a leading Chinese Internet services provider, and joined by ... multiple infectious disease product programs targeting antibiotic resistant infections ... Founded by Dr. Rodolphe Barrangou and ...
(Date:7/5/2017)... BOTHELL, Wash. , July 5, 2017   ... a leading developer, manufacturer and marketer of proprietary clinical ... cryopreservation freeze media ("BioLife"), today announced that ... ("WAVI") its debt holder and largest shareholder, to modify ... Pursuant to the modification, WAVI agreed to ...
Breaking Medicine Technology: